Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the MARIPOSA & PAPILLON data for J&J's RYBREVANT (amivantamab-vmjw) in EGFR-mutated lung cancer presented at ESMO 2023

Ticker(s): JNJ, AMGN

Who's the expert?

Institution: Cleveland Clinic

Vice Chair of the Department of Hematology and Medical Oncology at Cleveland Clinic Taussig Cancer Center.
Thoracic medical oncologist with over 20 years of clinical experience; Active clinical investigator in trials involving NSCLC and small cell lung cancer as well as mesothelioma.
Treats 20-25 new NSCLC patients per month and currently manages over 200 active patients with NSCLC.

Interview Goal

This interview will focus on discussing three Phase 3 studies (MARIPOSA, MARIPOSA-2 and PAPILLON) by Johnson and Johnson in EGFR-mutated lung cancer and the statistically significant and clinically meaningful progression-free survival endpoints presented at the 2023 ESMO conference

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.